Galenica is a diversified group active throughout the healthcare market which, among other things, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical services and access to databases and sets up networks. The Galenica Group enjoys a leading position in all its areas of activity - pharmaceutical manufacturing, pre-wholesaling, distribution, healthcare information and retailing. A large part of Galenica's income is generated by international operations. For more information please visit http://www.galenica.com.
Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercializing evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol ASPV and on the Toronto Stock Exchange under the trading symbol ASV. Learn more about the company at http://www.aspreva.com.
This news release contains forward-looking statements within the
meaning of the United States Private Securities Litigation Reform Act of
1995 and forward-looking information within the meaning of applicable
securities laws in Canada (collectively, "forward-looking statements"). The
words "anticipates", "believes", "budgets", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans", "projects",
"schedule", "should", "will", "would" and similar expressions are intended
to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking statements in
this news release include, but are not limited
|SOURCE Aspreva Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved